IPP Bureau
Zydus Wellness acquires U.K. based Comfort Click for Rs. 2,846 Cr
By IPP Bureau - August 31, 2025
Enters the high growth vitamins, minerals and supplements segment for adults, paediatrics, and animal health
GEA, JGC commission new spray dryer at Chugai Pharmaceutical in Japan
By IPP Bureau - August 31, 2025
This PSD-3, the first pharmaceutical spray dryer built by GEA for OEB-5 products, sets new standards for high-containment pharmaceutical spray drying
Bayer presents Phase III VICTOR clinical trial data of vericiguat at ESC Congress 2025
By IPP Bureau - August 31, 2025
The positive benefit-risk profile of vericiguat in its approved indication in patients with HFrEF following a recent heart failure event based on the pivotal Phase III VICTORIA trial remains unchanged
Roche, Alnylam to initiate Phase 3 cardiovascular outcomes trial of zilebesiran
By IPP Bureau - August 31, 2025
Zilebesiran, a potential best-in-disease RNAi anti-hypertensive with twice-yearly subcutaneous dosing, demonstrated encouraging safety when combined with two or more antihypertensives
Novo Nordisk taps Replicate Bioscience’s srRNA platform for obesity
By IPP Bureau - August 31, 2025
Replicate will receive research funding and could potentially receive up to approximately US$550 million
Apitoria Pharma receives 5 observations from USFDA for API facility
By IPP Bureau - August 31, 2025
At the end of the current inspection, a 'Form 483' was issued with 5 observations which are procedural in nature and no data integrity issues were reported
Novo Nordisk’s Wegovy cuts risk of heart attack, stroke or death by 57% compared to tirzepatide
By IPP Bureau - August 31, 2025
The study showed a significant 29% reduction in the risk for heart attack, stroke and death from any cause in the Wegovy users
FDA suspends Valneva’s license of chikungunya vaccine IXCHIQ in US
By IPP Bureau - August 31, 2025
The sudden subsequent decision to suspend IXCHIQ is based on updated VAERS data
FDA approves Novavax's Nuvaxovid 2025-2026 formula for prevention of COVID-19
By IPP Bureau - August 31, 2025
Nuvaxovid is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season
Lilly's Verzenio scores first OS improvement in breast Cancer
By IPP Bureau - August 30, 2025
Treatment with Verzenio also resulted in sustained invasive disease-free survival and distant relapse-free survival benefit
Accro Bioscience and Fosun Pharma ink agreement for TYK2/JAK1 Inhibitor in Greater China
By IPP Bureau - August 30, 2025
Accro will retain global rights to develop, manufacture, and commercialize AC-201 (excluding Chinese Mainland, Hong Kong SAR, and Macau SAR)
MHRA approves UK’s first new type of antibiotic for urinary tract infections
By IPP Bureau - August 30, 2025
As with any medicine, the MHRA will keep the safety of gepotidacin under close review
Dr Agarwal's Eye Hospital merges with parent Dr Agarwal's Health Care
By IPP Bureau - August 29, 2025
Merger is expected to streamline operations and provide unified management focus, driving efficiency and strategic alignment
FDA approves Teva Pharmaceuticals' first GLP-1 obesity drug
By IPP Bureau - August 29, 2025
Generic Saxenda is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the US market
